Apollo Therapeutics Ltd
Clinical trials sponsored by Apollo Therapeutics Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for tough blood cancers? early trial launches Results expected Mar 2027 (estimated)
- New hope for Hard-to-Treat cancers: APL-5125 enters human trials Results expected Apr 2027 (estimated)
- New vaccine aims to snuff out the common cold Results expected May 2027 (estimated)
- New drug APL-9796 tested for lung blood pressure disorder Results expected Aug 2027 (estimated)
-
New vaccine aims to snuff out the common cold
Vaccine OngoingThis early-stage trial is testing a new vaccine called APL-10456 that targets rhinovirus, the main cause of the common cold. About 144 healthy adults, both younger (18-54) and older (55+), will receive either the vaccine or a placebo. The main goal is to check if the vaccine is s…
Early phase 1 • Sponsor: Apollo Therapeutics Ltd • Aim: Vaccine
Last updated Jun 27, 2026 12:37 UTC
-
New hope for Hard-to-Treat cancers: APL-5125 enters human trials
Disease control OngoingThis study tests a new drug, APL-5125, in adults with advanced solid tumors like colorectal, pancreatic, and ovarian cancer. The goal is to see if the drug is safe and can shrink or control tumors. About 100 participants will receive the drug in two phases to find the best dose a…
Phase 1/2 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC